Authorized purpose: Aquilion ONE with Vitrea VSTP-001A provides whole-body CT acquisition and reconstruction with labeled FIRST, AiCE, spectral, cardiac, vascular, pulmonary, neurologic, abdominal, stone, gout, and embolization-planning applications in the associated Vitrea package.
Clinical role
CT acquisition, reconstruction, visualization, measurement, and labeled image-processing support.
Images and patients
CT/CTA · Whole body including head; brain, heart, lungs, liver, vessels, urinary stones, gout, and other anatomy represented in labeled CT workflows
Key limitation
Keep in mind: The exact CT system options and associated Vitrea applications have distinct modality, anatomy, protocol, and review limits; do not infer that every listed application is enabled at every site.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Aquilion ONE with Vitrea VSTP-001A provides whole-body CT acquisition and reconstruction with labeled FIRST, AiCE, spectral, cardiac, vascular, pulmonary, neurologic, abdominal, stone, gout, and embolization-planning applications in the associated Vitrea package.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Whole body including head; brain, heart, lungs, liver, vessels, urinary stones, gout, and other anatomy represented in labeled CT workflows Input: Supported X-ray projection data, protocols, patient studies, and reconstruction conditions.
Who uses it?Intended users: Qualified CT technologists and trained interpreting physicians.
What does the software produce?Output: Cross-sectional CT images, reformats, maps, measurements, and application-specific results.
What is its most important limitation?Key limitation: The exact CT system options and associated Vitrea applications have distinct modality, anatomy, protocol, and review limits; do not infer that every listed application is enabled at every site.
Clinical takeaway. Clinical role: Aquilion ONE with Vitrea VSTP-001A provides whole-body CT acquisition and reconstruction with labeled FIRST, AiCE, spectral, cardiac, vascular, pulmonary, neurologic, abdominal, stone, gout, and embolization-planning applications in the associated Vitrea package.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports phantom bench testing: image quality metrics for PIQE and SilverBeam, a phantom study in which PIQE showed 8 lp/cm greater high contrast spatial resolution than AIDR 3D, and a SilverBeam phantom dose study showing dose reduction. Representative body, cardiac, low dose chest and head images reviewed by an American Board Certified Radiologist were confirmed to be of diagnostic quality. Vitrea package improvements were assessed with phantom studies. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Aquilion ONE with Vitrea VSTP-001A provides whole-body CT acquisition and reconstruction with labeled FIRST, AiCE, spectral, cardiac, vascular, pulmonary, neurologic, abdominal, stone, gout, and embolization-planning applications in the associated Vitrea package.
The exact CT system options and associated Vitrea applications have distinct modality, anatomy, protocol, and review limits; do not infer that every listed application is enabled at every site.
The exact FDA document reports phantom bench testing: image quality metrics for PIQE and SilverBeam, a phantom study in which PIQE showed 8 lp/cm greater high contrast spatial resolution than AIDR 3D, and a SilverBeam phantom dose study showing dose reduction. Representative body, cardiac, low dose chest and head images reviewed by an American Board Certified Radiologist were confirmed to be of diagnostic quality. Vitrea package improvements were assessed with phantom studies. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance Testing - Bench PIQE Image Quality Evaluation CT image quality metrics were performed, utilizing phantoms, to assess" … "A phantom study was conducted and the subject device demonstrated 8 lp/cm greater high contrast spatial resolution compared to AIDR 3D.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports phantom bench testing: image quality metrics for PIQE and SilverBeam, a phantom study in which PIQE showed 8 lp/cm greater high contrast spatial resolution than AIDR 3D, and a SilverBeam phantom dose study showing dose reduction. Representative body, cardiac, low dose chest and head images reviewed by an American Board Certified Radiologist were confirmed to be of diagnostic quality. Vitrea package improvements were assessed with phantom studies. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance Testing - Bench PIQE Image Quality Evaluation CT image quality metrics were performed, utilizing phantoms, to assess" … "A phantom study was conducted and the subject device demonstrated 8 lp/cm greater high contrast spatial resolution compared to AIDR 3D.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K213504 FDA evidence package for Aquilion ONE (TSX-306A/3) V10.12 with Spectral Imaging System, Vitrea Software Package, VSTP-001A
DesignFDA 510(k) or PMA decision evidence and product verification described in the exact submission.
PopulationWhole body including head; brain, heart, lungs, liver, vessels, urinary stones, gout, and other anatomy represented in labeled CT workflows
Scopeexact submission
Tested versionAquilion ONE (TSX-306A/3) V10.12 with Spectral Imaging System, Vitrea Software Package, VSTP-001A configuration described in K213504
IndependenceSponsor or vendor study
K213504
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K213504 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported X-ray projection data, protocols, patient studies, and reconstruction conditions.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes CT acquisition and associated Vitrea image-processing applications with DICOM-based medical-image workflows.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the Aquilion ONE as a CT scanner consisting of a gantry, couch and a console used for data processing and display, and the Vitrea Software Package, VSTP-001A, as software applications integrated into Vitrea workstations. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Aquilion ONE (TSX-306A/3) V10.12 with Spectral Imaging System is a whole body multi-slice helical CT scanner, consisting of a gantry, couch and a console used for data processing and display." … "The VSTP-001A is a portfolio of software applications developed by Canon that are integrated into the Vital Images Vitrea workstations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the Aquilion ONE as a CT scanner consisting of a gantry, couch and a console used for data processing and display, and the Vitrea Software Package, VSTP-001A, as software applications integrated into Vitrea workstations. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Aquilion ONE (TSX-306A/3) V10.12 with Spectral Imaging System is a whole body multi-slice helical CT scanner, consisting of a gantry, couch and a console used for data processing and display." … "The VSTP-001A is a portfolio of software applications developed by Canon that are integrated into the Vital Images Vitrea workstations.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA package describes CT acquisition and associated Vitrea image-processing applications with DICOM-based medical-image workflows.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.
Only qualified ct technologists and trained interpreting physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K213504 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact CT system options and associated Vitrea applications have distinct modality, anatomy, protocol, and review limits; do not infer that every listed application is enabled at every site.
Exact FDA submission
Checked 2026-09-04
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact CT system options and associated Vitrea applications have distinct modality, anatomy, protocol, and review limits; do not infer that every listed application is enabled at every site.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K213504 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact CT system options and associated Vitrea applications have distinct modality, anatomy, protocol, and review limits; do not infer that every listed application is enabled at every site.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. computed tomography imaging system limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Authorized purpose: uOmnispace.CT provides healthcare institutions with tools to view, manipulate, evaluate, and analyze medical CT images, including colon, lung, vessel, brain, cardiac, liver, rib, spine, dual-energy, perfusion, and cardiovascular applications described in the exact FDA submission.
Modality
CT/CTA
Anatomy
Colon, lungs and airway, vessels, brain, heart, liver, ribs, spine, and other CT regions
Authorized purpose: uOmnispace.CT is software for viewing, manipulating, evaluating, and analyzing medical images within healthcare institutions. The FDA indication lists colon visualization, dental panoramic and paraxial reconstruction, lung and airway segmentation and quantitative parameters, nodule analysis, vessel and brain-perfusion analysis, heart and coronary analysis, calcium scoring, dynamic analysis, bone-structure labeling, liver evaluation, dual-energy processing, and cardiovascular combined analysis.
Modality
CT/CTA
Anatomy
Colon, jaw, lungs, airways, brain, heart, vessels, liver, spine, ribs, and other labeled CT regions
Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.